SGMO - Sangamo Therapeutics rises 5% on Q4 2022 earnings beats
- Sangamo Therapeutics ( NASDAQ: SGMO ) is up ~5% in after-hours trading Thursday after posting Q4 2022 financial results Wednesday that beat on the top and bottom lines.
- However, the company's net loss in the quarter widened ~39% to ~$52M (-$0.32 EPS vs -$0.26 EPS).
- Total operating expenses ~22% rose year over year to $82.6M.
- At the end of 2022, Sangamo ( SGMO ) had cash and cash equivalents of ~$307.5M, a ~34% decline from the end of 2021.
- Read why Seeking Alpha contributor Avisol Capitol Partners recently r eiterated its hold rating for Sangamo ( SGMO ).
For further details see:
Sangamo Therapeutics rises 5% on Q4 2022 earnings beats